Institut Gustave Roussy — Sponsor Intelligence | 48 EU Trials

Filter these 48 trials by condition, phase, country and more.

Open in Search →

48 Registered trials

31 Recruiting

15 Completed trials

15 Countries active

74 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I/II

Phase III: 14 Phase II: 24 Phase I/II: 5 Phase IV: 1 Phase I (Other): 2 Phase I (FiH): 2

Oversight events:

1 serious breach across 1 trial

View oversight register →

100%

15 of 15 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Non-small cell lung cancer 4 Head and neck cancer 2 Triple negative breast cancer 2 Rectal adenocarcinoma 2 Lung squamous cell carcinoma metastatic 1 Oesophageal squamous cell carcinoma metastatic 1 Squamous cell carcinoma of the cervix 1 Brain stem glioma 1 Colorectal cancer 1 Germ cell cancer 1 HER2 positive breast cancer 1 Squamous cell carcinoma of head and neck 1

Top IMPs

NIVOLUMAB 5 PEMBROLIZUMAB 5 ATEZOLIZUMAB 4 CISPLATIN 4 CARBOPLATIN 3 IPILIMUMAB 3 BEVACIZUMAB 2 CABOZANTINIB 2 CANNABIDIOL 2 CEMIPLIMAB 2 DURVALUMAB 2 ETOPOSIDE 2

All trials

48 total

Randomized, double-blind, Placebo-controlled, 2x2 cross over study assessing the efficacy and safety of cANnabidiol oral solution for joint … Not authorised

2023-505380-36-00 Phase III 1 country CANNABIDIOL
Randomized, double-blind, Placebo-controlled, 2x2 cross over study assessing the efficacy and safety of cANnabidiol oral solution for joint … Pending

2023-505380-36-01 Phase III 1 country CANNABIDIOL
Multicenter, randomized, double-blinded, placebo-controlled phase 3 trial to evaluate nonavalent HPV vaccine as a secondary prevention in pa… Pending

2024-520140-42-00 Phase III 1 country HUMAN PAPILLOMAVIRUS TYPE 31 L1 PROTEIN - ADSORBED - IN THE FORM OF VIRUS-LIKE P…
Phase II Clinical Trial of KORTUC (KRC-01) Combined with Radiotherapy for Locally Advanced Rectal Cancer: Towards a New Organ Preservation A… Pending

2025-524378-40-00 Phase II 1 country HYDROGEN PEROXIDE
Phase 2, Multicenter, Open label, Platform Study investigating Tarlatamab (AMG 757) in patients with Metastatic/Locally Advanced Small-Cell … Recruiting

2024-515847-47-00 Phase II 2 countries TARLATAMAB
Phase Ib study of the combination of regorafenib with conventional chemotherapy for the treatment of newly diagnosed patients with multimeta… Recruiting

2023-503322-39-00 Phase I (Other) 5 countries REGORAFENIB
Phase II trial of nivolumab for pediatric and adult relapsing/refractory ALK+ anaplastic large cell lymphoma, for evaluation of response in … Recruiting

2024-516807-17-00 Phase II 2 countries NIVOLUMAB
Phase 2, Multicenter, Open label, Platform Study investigating ASP3082 in patients with Metastatic/Locally Advanced Non-Small-Cell Lung Canc… Recruiting

2025-522533-54-00 Phase II 1 country ASP3082; GLUCOSE, ANHYDROUS
An open label phase II platform modular study exploring the efficacy and safety of the Valemetostat (EZH1/2 inhibitor) in patients with sele… Recruiting

2024-519788-16-00 Phase II 1 country VALEMETOSTAT TOSILATE
A Randomized, Open-labelled, Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard… Recruiting

2025-521634-29-00 Phase III 2 countries AZACITIDINE; VENETOCLAX
A randomized multicenter Phase II trial evaluating oral pooled fecal microbiotherapy (MaaT033) concomitant to Cemiplimab (CB) versus best in… Recruiting

2024-517018-14-00 Phase II 1 country ALLOGENEIC FAECAL MICROBIOTA, POOLED; CEMIPLIMAB
A short-term preoperative, window-of-opportunity study, evaluating activity and safety of Elacestrant monotherapy as compared to Elacestrant… Recruiting

2024-520051-24-00 Phase II 1 country ELACESTRANT DIHYDROCHLORIDE; LEUPRORELIN ACETATE
Cabozantinib and Nivolumab among older patients with renal-cell carcinoma, a prospective cohort with geriatric, pharmacologic and patient-re… Recruiting

2024-516650-22-00 Phase IV 1 country CABOZANTINIB; NIVOLUMAB
First-line immunotherapy-based standard of care and local ablative treatments for oligometastatic non-small cell lung cancer patients: a ran… Recruiting

2023-503326-39-00 Phase III 1 country ATEZOLIZUMAB; CARBOPLATIN; CEMIPLIMAB; CISPLATIN; DURVALUMAB; IPILIMUMAB; NIVOLU…
HR-NBL2: High-risk neuroblastoma study 2.0 of SIOP-Europe- Neuroblastoma/SIOPEN: Randomised, international and multicentric phase 3 study t… Recruiting

2024-514917-36-00 Phase III 13 countries BUSULFAN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DINUTUXIMAB BETA; ETOPOSIDE;…
Immunotherapy and chemotherapy treatment or no treatment guided by the level of tumour-infiltrating cells in resected early-stage triple-neg… Recruiting

2023-504620-26-00 Phase II 2 countries PEMBROLIZUMAB
tislelizUMaB in canceR patients with molEcuLar residuaL disease (UMBRELLA) Recruiting

2023-503316-33-00 Phase III 1 country SODIUM CHLORIDE; TISLELIZUMAB
Pan-lesions SBRT combined with lymphocyte support through ATRA-driven blockade of MDSC in patients with oligometastatic solid cancer (LySATR… Recruiting

2022-500680-13-00 Phase I/II 1 country TRETINOIN
Choice Of the Most Active Strategies for Short term recurring Triple Negative Breast Cancer A phase Ib/II, open-label, modular, dose-finding… Recruiting

2023-503606-36-00 Phase I/II 1 country
Refining Adjuvant treatment IN endometrial cancer Based On molecular features, TransPORTEC platform trials – p53abn - RED Randomized phase … Recruiting

2023-503886-44-00 Phase III 1 country OLAPARIB
CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA Recruiting

2023-503317-29-00 Phase III 10 countries AXITINIB; CABOZANTINIB; IPILIMUMAB; LENVATINIB; NIVOLUMAB; PEMBROLIZUMAB
Multicenter randomized Phase III trial evaluating contact X-ray brachytherapy for rectal preservation in intermediate substage rectal adenoc… Recruiting

2023-506885-30-00 Phase III 1 country CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN HYDROCHLORIDE TRIHYDRATE; O…
Phase 1b/2, Multicenter, Open-label, Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3-DXd m… Recruiting

2023-505925-15-00 Phase I (FiH) 1 country
Study evaluating thromboprophylaxis in patients with advanced germ cell tumours of good or intermediate prognosis Recruiting

2022-502426-41-00 Phase III 1 country CISPLATIN; DALTEPARIN SODIUM; ENOXAPARIN SODIUM; TINZAPARIN SODIUM

Showing 1–24 of 48 trials

← All sponsors A–Z